Quest Diagnostics Study Reveals Alarming Spread of Drug-Resistant UTI Bacteria — Quest Diagnostics

Event summary

A national study by Quest Diagnostics and Hackensack Meridian CDI found 69.5% of Klebsiella pneumoniae samples resistant to common oral antibiotics.
The study analyzed 2,000 samples across 42 states, identifying 267 multidrug-resistant sequence types.
100% of the bacteria investigated were classified as multidrug resistant, with the CTX-M-15 gene being the main culprit in resistance spread.
The research highlights a dangerous shift from hospital-associated to community-associated infections.
The study was published in Nature Communications on June 18, 2026.

The big picture

This study underscores the growing threat of antibiotic resistance in community settings, shifting the focus from hospital-acquired infections to everyday infections resistant to common treatments. Quest Diagnostics' collaboration with Hackensack Meridian CDI highlights the importance of commercial clinical labs in informing public health and driving research. The findings could spur investment in antibiotic innovation and public health initiatives to combat the spread of drug-resistant bacteria.

What we're watching

Treatment Development: How the genetic blueprint provided by this study will accelerate the development of new vaccines or treatments for vulnerable patients.
Public Health Response: Whether regulatory agencies will increase surveillance and control measures for community-associated multidrug-resistant infections.
Antibiotic Innovation: The pace at which new oral treatment options will be developed to address the urgent need highlighted by the study.